Contraception and Family Planning — MCQs

Contraception and Family Planning Indian Medical PG Practice Questions and MCQs

Question 501: What is the most common side effect of an Intrauterine Contraceptive Device (IUCD) that necessitates its removal?

A. Bleeding
B. Pain (Correct Answer)
C. Pelvic infection
D. Ectopic pregnancy

Explanation: The correct answer is **Pain (Option B)**. ### **Explanation** While **bleeding** (menorrhagia or intermenstrual spotting) is statistically the **most common side effect** overall associated with IUCD use, **pain** (dysmenorrhea or pelvic cramping) is the **most common reason for medical removal** of the device. The underlying medical concept is based on patient tolerance: most women can manage or be treated for increased menstrual flow with NSAIDs or antifibrinolytics. However, persistent or severe pelvic pain is often perceived as intolerable or indicative of complications (like displacement or PID), leading both the patient and the clinician to opt for removal. ### **Analysis of Incorrect Options** * **A. Bleeding:** This is the most frequent side effect, but it is second to pain as a reason for discontinuation/removal. * **C. Pelvic Infection:** While IUCDs (specifically the insertion process) slightly increase the risk of Pelvic Inflammatory Disease (PID) in the first 20 days, it is a relatively rare complication and not the primary reason for removal. * **D. Ectopic Pregnancy:** An IUCD significantly reduces the *absolute* risk of ectopic pregnancy by preventing pregnancy overall. However, if a woman *does* conceive with an IUCD in situ, the *relative* risk that the pregnancy is ectopic is higher. ### **High-Yield Clinical Pearls for NEET-PG** * **Most common side effect:** Bleeding. * **Most common cause for removal:** Pain. * **Most common complication:** Expulsion (most likely to occur in the first 3 months, during menstruation). * **Ideal time for insertion:** Within 10 days of the onset of menstruation (to ensure the patient is not pregnant and the cervix is slightly dilated). * **Mechanism of Action (Cu-T):** Primarily a sterile inflammatory response in the endometrium which is spermicidal.

Question 502: Intercourse can be cumbersome, annoying, or noisy with the use of which of the following contraceptive methods?

A. Male condom
B. Female condom (Correct Answer)
C. Intrauterine contraceptive device (IUCD)
D. Vaginal ring

Explanation: **Explanation:** The correct answer is **B. Female Condom**. The female condom (e.g., FC2) is a loose-fitting sheath made of polyurethane or nitrile. It features two rings: an internal ring for stabilization against the cervix and a larger external ring that remains outside the vulva. Because it is not form-fitting and is made of relatively thin, non-latex material, it can move during coitus, often producing a **"rustling" or "squeaking" noise**. Additionally, its bulky design and the presence of the external ring can be perceived as **cumbersome or aesthetically annoying** by some users, leading to lower acceptability rates compared to other methods. **Why other options are incorrect:** * **Male Condom:** While it may occasionally slip or break, it is form-fitting and generally silent during intercourse. * **IUCD:** Once inserted by a healthcare provider, the device remains inside the uterus. Except for the thin nylon strings (which may occasionally be felt by the partner), it does not interfere with the mechanics or sound of intercourse. * **Vaginal Ring:** These are flexible, soft rings placed in the upper vagina. They are designed to be unobtrusive; most couples do not feel them during intercourse, and they do not produce noise. **Clinical Pearls for NEET-PG:** * **Dual Protection:** The female condom is the only female-initiated method that provides significant protection against both pregnancy and STIs (including HIV). * **Material:** Unlike many male condoms, female condoms are often **latex-free** (nitrile), making them safe for those with latex allergies and compatible with oil-based lubricants. * **Failure Rate:** The typical use failure rate is approximately **21%**, which is higher than the male condom (approx. 13-18%). * **Pre-insertion:** It can be inserted up to 8 hours before intercourse, unlike the male condom which requires an erect penis for application.

Question 503: What is the cumulative pregnancy rate at 5 years for a levonorgestrel intra-uterine device (LNG-IUD)?

A. 0.5% (Correct Answer)
B. 1%
C. 1.5%
D. 2%

Explanation: The **Levonorgestrel Intrauterine System (LNG-IUD)**, specifically the 52mg version (Mirena), is one of the most effective forms of Long-Acting Reversible Contraception (LARC). ### **Explanation of the Correct Answer** The correct answer is **0.5% (Option A)**. According to large-scale clinical trials and the Pearl Index, the cumulative failure rate for the LNG-IUD over 5 years of use is approximately **0.5 to 0.8 per 100 women**. Its high efficacy is attributed to its local mechanism: thickening of cervical mucus (preventing sperm penetration), inhibition of sperm motility, and endometrial suppression. Unlike oral pills, its efficacy is not dependent on patient compliance, making its "typical use" failure rate nearly identical to its "perfect use" rate. ### **Analysis of Incorrect Options** * **Option B (1%):** This is closer to the failure rate of the **Copper T 380A** (approx. 0.8% in the first year and cumulative ~2% at 10 years). * **Options C and D (1.5% - 2%):** These rates are too high for the LNG-IUD. These figures are more characteristic of less effective methods like the progestogen-only pill (POP) or barrier methods under typical use. ### **High-Yield Clinical Pearls for NEET-PG** * **Most Effective Contraceptive:** The **Progestogen Implant (Nexplanon)** is technically the most effective (0.05% failure rate), followed closely by the LNG-IUD and Vasectomy. * **Non-Contraceptive Benefits:** LNG-IUD is the **Gold Standard** (medical management of choice) for **Heavy Menstrual Bleeding (HMB)** and Adenomyosis. * **Duration:** While traditionally approved for 5 years, recent evidence suggests efficacy for up to 8 years for pregnancy prevention. * **Mechanism:** Primarily local; it does **not** consistently inhibit ovulation (ovulation is maintained in ~75-85% of cycles).

Question 504: Centchroman is:

A. A new drug for fibroids
B. A new drug for endometriosis
C. An injectable contraceptive
D. A nonsteroidal oral contraceptive (Correct Answer)

Explanation: **Explanation:** **Centchroman (Ormeloxifene)** is a unique **non-steroidal, non-hormonal oral contraceptive** developed by the Central Drug Research Institute (CDRI), Lucknow, India. It belongs to the class of **Selective Estrogen Receptor Modulators (SERMs)**. It works by antagonizing estrogen receptors in the uterus, thereby altering the endometrial receptivity and preventing the implantation of the blastocyst. Since it does not suppress ovulation, the normal hormonal milieu of the body remains undisturbed. **Analysis of Options:** * **Option A & B:** While SERMs are sometimes explored for estrogen-dependent conditions, Centchroman is primarily indicated and marketed as a contraceptive and for the treatment of Dysfunctional Uterine Bleeding (DUB). It is not the standard "new drug" for fibroids (where Ulipristal or GnRH analogues are used) or endometriosis (where Dienogest or GnRH analogues are preferred). * **Option C:** Centchroman is an **oral pill**, not an injectable. Common injectables include DMPA (Antara program) and NET-EN. * **Option D:** This is correct as Centchroman is the only non-steroidal oral contraceptive pill available, famously known by the brand names **Saheli** or **Chhaya** (under the National Family Planning Program). **High-Yield Clinical Pearls for NEET-PG:** * **Dosage Schedule:** 30 mg **twice weekly** for the first 3 months, followed by **once weekly** thereafter. * **Major Side Effect:** The most common side effect is a **prolonged menstrual cycle** (delayed periods), which occurs in about 8% of users. * **Safety Profile:** It has no steroid-related side effects like weight gain, nausea, or mood swings, and it is safe for use during **lactation**. * **Other Uses:** It is highly effective in treating **Mastalgia** and **Dysfunctional Uterine Bleeding (DUB)**.

Question 505: Which of the following is considered a natural method of contraception?

A. Rhythm method
B. Coitus interruptus
C. Lactational amenorrhea method
D. All of the above (Correct Answer)

Explanation: **Explanation:** Natural methods of contraception, also known as **Behavioral Methods**, rely on avoiding intercourse during fertile periods or preventing the deposition of sperm in the vagina without the use of artificial devices, hormones, or chemicals. * **Rhythm Method (Calendar Method):** This is a periodic abstinence method where a woman tracks her menstrual cycle to predict ovulation. By calculating the "fertile window" (typically days 10–17 in a 28-day cycle) and avoiding unprotected intercourse during this time, pregnancy is prevented. * **Coitus Interruptus (Withdrawal):** This is the oldest recorded method. It involves the male withdrawing the penis from the vagina before ejaculation occurs, thereby preventing the entry of sperm into the female reproductive tract. * **Lactational Amenorrhea Method (LAM):** This relies on the physiological suppression of ovulation caused by high prolactin levels during exclusive breastfeeding. For LAM to be effective, three criteria must be met: the mother must be amenorrheic, the baby must be <6 months old, and breastfeeding must be exclusive (day and night). Since all three options utilize natural physiological processes or behavioral modifications rather than external agents, **Option D** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** 1. **Failure Rate:** Natural methods have the highest **Pearl Index** (typical use failure rate) compared to modern methods. 2. **LAM Efficacy:** LAM is 98% effective only if all three criteria are strictly met. 3. **Billings Method:** Also known as the **Cervical Mucus Method**, it is another natural method where the woman observes changes in mucus consistency (ovulatory mucus is thin, watery, and stretchy—*Spinnbarkeit effect*). 4. **Standard Days Method:** A variation of the rhythm method suitable for women with cycles between 26–32 days; days 8–19 are considered fertile.

Question 506: Copper-T is preferably inserted postnatally after how many weeks?

A. 2 weeks
B. 4 weeks
C. 5 weeks
D. 8 weeks (Correct Answer)

Explanation: **Explanation:** The timing of Copper-T (IUCD) insertion post-delivery is critical to minimize complications such as expulsion and uterine perforation. **1. Why 8 weeks is the correct answer:** The standard recommendation for "interval" postpartum IUCD insertion is **6 to 8 weeks** after delivery. By this time, **complete uterine involution** has occurred. Inserting the device after the uterus has returned to its non-pregnant size and the cervix has closed significantly reduces the risk of spontaneous expulsion and accidental perforation of the soft, postpartum uterine wall. **2. Analysis of Incorrect Options:** * **A (2 weeks) & B (4 weeks):** These periods fall within the "sub-involution" phase. Inserting an IUCD between 48 hours and 6 weeks postpartum is generally avoided because the uterus is still large and friable, leading to a very high rate of expulsion and increased infection risk. * **C (5 weeks):** While closer to the involution period, it is still prior to the standard 6–8 week follow-up. Most clinical guidelines (including WHO and National Health programs) synchronize insertion with the postnatal check-up at 6–8 weeks to ensure safety. **3. High-Yield Clinical Pearls for NEET-PG:** * **PPIUCD (Postpartum IUCD):** Can be inserted within **48 hours** of delivery (ideally within 10 minutes of placental delivery). If not done within 48 hours, it is contraindicated until 6 weeks. * **Post-Abortal Insertion:** Can be done **immediately** (First trimester) or after 1 week (Second trimester), provided there is no infection. * **Mechanism of Action:** Copper-T primarily acts as a **spermicide** by causing a sterile inflammatory response in the endometrium and altering tubal motility. * **Most Common Side Effect:** Excessive menstrual bleeding (Menorrhagia). * **Most Common Reason for Removal:** Pain and bleeding.

Question 507: Which of the following is NOT an absolute contraindication for oral contraceptive pills?

A. Valvular heart disease
B. Migraine with focal aura
C. History of breast cancer
D. Smoking (Correct Answer)

Explanation: In the context of Combined Oral Contraceptive Pills (COCPs), it is crucial to distinguish between **Absolute Contraindications (WHO Category 4)** and **Relative Contraindications (WHO Category 3)**. ### Why Smoking is the Correct Answer Smoking is **not** an absolute contraindication for all women. According to the WHO Medical Eligibility Criteria (MEC), smoking is only an absolute contraindication (Category 4) if the woman is **$\geq$ 35 years old and smokes $\geq$ 15 cigarettes per day**. For women under 35 or those who smoke fewer than 15 cigarettes, it is considered a relative contraindication. Therefore, "Smoking" as a standalone option is not an absolute contraindication. ### Why Other Options are Wrong (Absolute Contraindications) * **Valvular Heart Disease:** If complicated by pulmonary hypertension, atrial fibrillation, or a history of subacute bacterial endocarditis, it is Category 4 due to the high risk of thromboembolism. * **Migraine with Focal Aura:** Estrogen increases the risk of ischemic stroke. Migraine with aura at any age is a Category 4 contraindication. * **History of Breast Cancer:** Breast cancer is a hormone-dependent tumor. Any current or past history of breast cancer is Category 4 because exogenous estrogen can stimulate tumor growth or recurrence. ### High-Yield Clinical Pearls for NEET-PG * **Mnemonic for Absolute Contraindications (C-H-E-C-K):** **C**ancer (Breast/Genital), **H**eart disease/Hypertension ($\geq$160/100), **E**mbolism (DVT/PE), **C**oagulation disorders, **K**liver (Liver) disease/Cirrhosis. * **Undiagnosed Vaginal Bleeding:** This is an absolute contraindication until malignancy is ruled out. * **Postpartum:** COCPs are contraindicated for the first 3 weeks postpartum due to high VTE risk, and for 6 months if breastfeeding (Category 4).

Question 508: What is the safest method of contraception in sickle cell anemia?

A. Oral contraceptive pill
B. Intrauterine contraceptive device (IUCD)
C. Barrier method (Correct Answer)
D. Progestin-only pill or implant

Explanation: **Explanation:** The primary concern in managing contraception for patients with **Sickle Cell Anemia (SCA)** is avoiding methods that increase the risk of thromboembolism or trigger a vaso-occlusive crisis. **Why Barrier Methods are the Correct Choice:** Barrier methods (like condoms) are considered the **safest** because they are non-hormonal and non-invasive. They have zero systemic side effects and do not interfere with blood viscosity or coagulation factors, thereby posing no risk of precipitating a sickle cell crisis. **Analysis of Incorrect Options:** * **Oral Contraceptive Pills (OCPs):** Combined OCPs contain estrogen, which is **pro-thrombotic**. In SCA, where the risk of stroke and vaso-occlusion is already high, estrogen is generally avoided as it significantly increases the risk of thromboembolic events. * **Intrauterine Contraceptive Device (IUCD):** Copper-T can increase menstrual blood loss (menorrhagia) and pelvic pain. In anemic patients (like those with SCA), any method that increases blood loss is undesirable. Furthermore, the risk of pelvic infection can trigger a crisis. * **Progestin-only methods:** While Progestin-only pills (POPs) or Depo-Provera (DMPA) are actually **preferred** over estrogen-containing pills because they may reduce the frequency of crises, they still carry a higher systemic profile compared to the absolute safety of barrier methods in terms of immediate complications. **NEET-PG High-Yield Pearls:** * **DMPA (Depo-Provera)** is often cited in clinical guidelines as a highly effective choice for SCA because it stabilizes red cell membranes and can **reduce the frequency of painful crises**. * However, when the question asks for the **safest** (implying least systemic interference), **Barrier methods** are the answer. * **Estrogen** is the "enemy" in SCA due to the risk of thrombosis.

Question 509: Spermicide acts by which of the following mechanisms?

A. Release of acrosomal enzymes (Correct Answer)
B. Lysis of cell membrane
C. Inhibition of glucose uptake
D. Alteration of vaginal enzymes

Explanation: **Explanation:** Spermicides are chemical barrier methods of contraception. The most commonly used active ingredient in spermicides is **Nonoxynol-9**, which is a surfactant. **1. Why Option A is Correct:** The primary mechanism of action for spermicides involves the disruption of the sperm's surface. When the surfactant (Nonoxynol-9) comes into contact with the sperm, it causes a physical disruption of the sperm cell membrane. This disruption leads to the **premature release of acrosomal enzymes** (such as hyaluronidase and acrosin). Since these enzymes are released prematurely before reaching the ovum, the sperm loses its ability to penetrate the zona pellucida, effectively rendering it incapable of fertilization. **2. Why Other Options are Incorrect:** * **Option B (Lysis of cell membrane):** While spermicides do disrupt the membrane, "lysis" implies total disintegration. The specific functional failure that prevents pregnancy is the premature acrosomal reaction triggered by membrane damage. * **Option C (Inhibition of glucose uptake):** This is not a recognized mechanism for chemical spermicides. Sperm motility is affected by membrane damage rather than metabolic starvation. * **Option D (Alteration of vaginal enzymes):** Spermicides do not work by changing vaginal enzymes; they act directly on the sperm cell. **High-Yield Clinical Pearls for NEET-PG:** * **Active Ingredient:** Nonoxynol-9 is the most common agent. * **Failure Rate:** High typical failure rate (~18-28%) when used alone. * **STI Risk:** Frequent use of Nonoxynol-9 can cause vaginal/rectal irritation and mucosal micro-abrasions, which may actually **increase** the risk of HIV and other STI transmission. * **Application:** Must be applied high in the vagina near the cervix at least 10–15 minutes before intercourse.

Question 510: Which of the following ultrasound features during the second trimester is NOT a marker of Down syndrome?

A. Single umbilical artery
B. Choroid plexus cyst (Correct Answer)
C. Diaphragmatic hernia
D. Duodenal atresia

Explanation: In the second trimester, ultrasound markers for chromosomal abnormalities are categorized into "soft markers" and structural anomalies. **Why Choroid Plexus Cyst (CPC) is the correct answer:** While choroid plexus cysts are associated with aneuploidy, they are specifically and strongly linked to **Trisomy 18 (Edwards Syndrome)**, not Down syndrome (Trisomy 21). In the absence of other structural anomalies, an isolated CPC is often a transient, benign finding in a normal fetus. **Analysis of Incorrect Options (Markers for Down Syndrome):** * **Single Umbilical Artery (SUA):** While often isolated, SUA is associated with various chromosomal issues, including Trisomy 21 and 18, as well as renal and cardiac malformations. * **Diaphragmatic Hernia:** This structural defect is associated with an increased risk of chromosomal abnormalities, including Trisomy 21, 18, and 13. * **Duodenal Atresia:** This is a classic "high-yield" marker for Down syndrome. Approximately **30% of fetuses** with duodenal atresia (visualized as the "double bubble" sign) have Trisomy 21. **High-Yield NEET-PG Pearls:** * **Most sensitive soft marker for Down Syndrome:** Increased Nuchal Translucency (1st trimester) or Thickened Nuchal Fold (2nd trimester). * **Most specific structural marker:** Duodenal atresia. * **Other Down Syndrome markers:** Echogenic intracardiac focus (EIF), ventriculomegaly, short femur/humerus, and hyperechoic bowel. * **Trisomy 18 associations:** Strawberry-shaped skull, clenched fists with overlapping fingers, rocker-bottom feet, and **Choroid Plexus Cysts**.

Practice by Chapter

Natural Family Planning Methods

Practice Questions

Barrier Methods

Practice Questions

Hormonal Contraceptives

Practice Questions

Intrauterine Devices

Practice Questions

Emergency Contraception

Practice Questions

Permanent Contraception Methods

Practice Questions

Contraception in Special Populations

Practice Questions

Contraceptive Counseling

Practice Questions

Side Effects and Complications of Contraceptives

Practice Questions

Future Contraceptive Technologies

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free